Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 58

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 58
---
 cash at closing, minus $2.7 million, plus a contingent value right (“CVR”) for up to 90% of the near-term net proceeds from the sale of the Company’s legacy assets. XRC’s proposal
contemplated there would be two separate cash payment tranches, one payment through a distribution prior to receiving shareholder approval and a second payment at the closing of the plan of arrangement.

On October 8, 2025, Party B notified the Company that it would not be proceeding with a transaction for the acquisition of RP-3467 due to its lack of internal support for the proposed clinical development plan. Later on October 8, 2025, Leerink Partners and Company management contacted Party A, who expressed interest in re-engaging in the process for the acquisition of RP-3467 and, subsequently, on October 14, 2025, Party A re-initiated diligence
and the drafting of an asset purchase agreement for such assets of the Company began.

On October 21, 2025, XRC provided a revised
proposal for the acquisition of the Company through a plan of arrangement. The proposal indicated that XRC, or an affiliate, would be willing to acquire the Company for

32

net cash at closing, minus $4.0 million, plus a CVR for up to 90% of the near-term net proceeds from the sale of the Company’s legacy assets, the increased transaction fee attributable
to Party B’s decision to withdraw its offer for RP-3467. Also at this meeting, representatives of Stikeman advised the Transaction Committee on the feasibility of having two separate cash payment
tranches as contemplated in XRC’s proposals, particularly with regard to tax and other practical considerations. Following such discussion, it was decided to revise the proposal to provide for a single cash payment at closing, which was viewed
as being an immaterial change in light of the transactions overall expected timeline.

Following financial diligence from September
through early October, XRC and Party D submitted best and final non-binding proposals on October 27 and 29, 2025, respectively.

On October 29, 2025, the Board met to receive an update on the strategic transaction process from the Transaction Committee. The
Transaction Committee reported on the status of the process, the number of potential counterparties the Company had engaged with, the proposals received and the process through which the Transaction Committee had determined that the proposal from
XRC represented the most attractive proposal the Company had received due to